David A. Weinstein, M.D, M.M.Sc. Director; Glycogen Storage Disease Program Milan Italy October 2, 2010 Gene Therapy in the Canine Model of GSD Ia.

Slides:

Advertisements

Similar presentations

International meeting

Advertisements

Clinical Course of Untreated BA Phoebe part. Clinical Course of Untreated BA Most present within four to six weeks of conjugated jaundice and acholic.

Stephen G. Kaler, M.D. Molecular Medicine Program Section on Translational Neuroscience National Institute of Child Health & Human Development National.

Endocrine Module 1b. Pancreas Gland 6 ” long Horizontal Behind stomach Upper left abdominal quadrant Both endocrine & exocrine functions.

NYU Department of Medicine Grand Rounds Clinical Vignette Elizabeth Haskins, PGY 3 February 25, 2009.

Women and Adolescents Case Presentations Vivian M Tamayo-Agrait, MD, FACOG, AAHIVMS Department of Obstetrics and Gynecology University of Puerto Rico Faculty,

Chapter 11 Newborn Screening. Introduction Newborns can be screened for an increasing variety of conditions on the principle that early detection can.

Blood glucose levels and Vascular Disease. Chronic elevation of blood glucose levels leads to the endothelium cells taking in more glucose than normal.

What is Pompe Disease? What does it look like?

Diabetes Mellitus.

Phenylketonuria By John Fenlon March of Dimes 2009.

Ryan Smith October 20,  Rare inherited eye disease (1 in 80,000)  Symptoms first occur in early infancy ◦ Irregular behavior, nystagmus  Progresses.

Gene therapy for eye disease UCL Institute of Ophthalmology Department of Genetics An experimental technique that uses the delivery of genetic material.

for pregnant women and new moms

Control of Energy The Original Biofuels. Importance of Glucose Regulation Too little – Brain problems Too much –Osmotic water loss (cellular and systemic)

SITUATION Hypoglycaemia – blood glucose level

Wyoming Department of Health Communicable Diseases

Normal Metabolism: In Response to Insulin, the Liver Continuously Micromanages Glucose Pancreas Liver Clears 50% - 80% of insulin Stores 30%-50% of glucose.

Nurses SOAR! Training Curricula Series For More Information and Inquiries:

Regulation of insulin levels Starter: what do each of the following cells produce and are they part of the endocrine or exocrine system; –α cells –β cells.

Pediatric Endocrinology Use of Biologic and Chemotherapeutic Agents Pediatric Endocrinology Use of Biologic and Chemotherapeutic Agents.

BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.

Gilles Mithieux-Fabienne Rajas

BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.

Fabienne Rajas-Gilles Mithieux Inserm u.855/Université Lyon 1 October 2 nd, 2010, Milan MRAR Gene therapy correction in the liver-specific GSD1a mouse.

Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) Trial IDEAL Trial Presented at The American Heart Association Scientific.

Gene Therapy. Gene Therapy is a technique for correcting defective genes responsible for disease development Gene Therapy is a technique for correcting.

Jordan Jones Lauren Johnson. What is it? Gene therapy, also known as genetic modification, is a technique for correcting faulty genes that are responsible.

Fabry disease in donor kidneys with 3 and 12 years follow-up after transplantation Willy Aasebø 1, Erik H. Strøm 2, Torstein Hovig 2, Liv H. Undset 1 Arvid.

Our patient, a 22 year old female, had been diagnosed at 3 ½ months of age. Her metabolic control had never been good and she presented to hospital with.

Metabolic Activation Therapy Premilinary Information for Endocrinologists.

Protection of Human Subjects Case #2

1 Ch 14 Notes I. Mutations A. Def - a change in the ___________or ___________ of the genetic material of an organism. B. Causes 1. __________ – factors.

Advances in Mitochondrial Disease

What is... Gene Therapy?. Genes Specific sequence of bases that encode instructions on how to make genes. Genes are passed on from parent to child. When.

“Little Man” 2/18/16. Signalment and history 8 year old MC Maltese dog ~2-3 week history of increased liver enzymes noted at rDVM before dental & anesthesia.

Understanding Prostate Myths

CASE 4 44 yo man HIV positive 2010 CD4 400 on diagnosis Initiated Abacavir/3TC/Dolutegravir in /2013 CD4 600 HIV viral load

Composition of Blood Blood has two major components:

Gene therapy for heart failure

Blood Glucose Noadswood Science, 2016.

Long-Term Efficacy and Safety of Insulin and Glucokinase Gene Therapy for Diabetes: 8-Year Follow-Up in Dogs Maria Luisa Jaén, Laia Vilà, Ivet Elias,

Glycogen Storage Diseases

Molecular Therapy - Methods & Clinical Development

What is ... Gene Therapy?.

Targeting Visceral Fat by Intraperitoneal Delivery of Novel AAV Serotype Vector Restricting Off-Target Transduction in Liver Wei Huang, Xianglan Liu,

By Dr. Dipendra Raj Pandeya, PhD Assistant Professor Department of Clinical Laboratory Science College of Applied Medical Sciences Al Jouf University.

Pharmacokinetics: Theophylline

Time Restricted Eating for Non-Alcoholic Fatty Liver Disease & Obesity

The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America Present HCV Guidance: Recommendations for Testing,

Gene Therapy: Past, Present, and Future

Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1.

Volume 9, Issue 2, Pages (February 2004)

Volume 16, Issue 4, Pages (April 2008)

Anti-Inducible Costimulator Monoclonal Antibody Treatment of Canine Chronic Graft- versus-Host Disease Scott S. Graves, Maura H. Parker, Diane Stone,

Volume 14, Issue 1, Pages (July 2006)

Targeting Visceral Fat by Intraperitoneal Delivery of Novel AAV Serotype Vector Restricting Off-Target Transduction in Liver Wei Huang, Xianglan Liu,

Volume 22, Issue 10, Pages (October 2014)

Long-Term Efficacy and Safety of Insulin and Glucokinase Gene Therapy for Diabetes: 8-Year Follow-Up in Dogs Maria Luisa Jaén, Laia Vilà, Ivet Elias,

Volume 9, Issue 6, Pages (June 2004)

Molecular Therapy - Methods & Clinical Development

Volume 26, Issue 3, Pages (March 2018)

Volume 18, Issue 11, Pages (November 2010)

Volume 19, Issue 6, Pages (June 2011)

Volume 1, Issue 2, Pages (February 2000)

Drug Therapy in Pediatric Patients

Volume 18, Issue 6, Pages (June 2010)

Efficacy of Helper-dependent Adenovirus Vector-mediated Gene Therapy in Murine Glycogen Storage Disease Type Ia Dwight D Koeberl, B Sun, A Bird, YT Chen,

Molecular Therapy - Methods & Clinical Development

Presentation transcript:

David A. Weinstein, M.D, M.M.Sc. Director; Glycogen Storage Disease Program Milan Italy October 2, 2010 Gene Therapy in the Canine Model of GSD Ia

The GSD dogs Naturally occurring in maltese Mutation 1 codon away from human mutation Associated with no enzyme activity Clinically identical to humans Prior to study, no dog had survived more than 4 weeks

Gene Therapy in Dogs with GSD Undetectable glucose at birth Confirmed by mutation analysis on DOL #1

Gene therapy was performed on our dogs with GSD type Ia for the first time on September 11, 2007 Vector: AAV-8 Dose: 5 x vector genomes/kg Method: IV injection into the jugular vein

Fasting Blood Glucose 2 wks post-injection of rAAV2/8

Untreated GSDIa affected dog 18 days old Treated GSDIa affected dog 17 days old 16 days post AAV8 treatment

Effect of Gene Therapy Waned by 8 Weeks

Second Gene Therapy Treatment at 4-1/2 months of age 1 x viral genomes/kg injected into the hepatic portal vein using AAV-1 as the vector

GSDIarAAV2/8+rAAV2/1Carrier Control Fasting Study 7 weeks after AAV-1 infusion

All glucose support was stopped at 6 months of age No problems clinically while weaning off therapy On the day after all support was stopped, dog went 22 hours without food yet remained clinically well

Dulce: Off Therapy for 19 months (21 months following last gene therapy treatment) Liver biopsy 6 months after the 2 nd gene therapy dose demonstrated 7% activity

H & E Staining

No adenomas or evidence of complications 3 years after initial therapy While the 2 year metabolic lipids and liver function tests have continued to improve, lactates have begun to rise with stress Third gene therapy treatment performed in Feb 2010 Gene Therapy Update

Introducing the New Puppies Born April 9, 2010 TuckerJasmine

Gene Therapy Update Gene therapy performed at 36 hours of life By 2 weeks, puppies able to fast for 6 hours (baseline minutes) Glucose support discontinued at 3 weeks

Gene Therapy Summary Gene therapy appears to be a promising therapy for the future Planning to treat 5 other dogs this year using G-6-pase regulated by the human promoter If successful, same technique could be used to treat many other genetic diseases of the liver

Thank you For more information on the research, please visit our website